Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C22H30O2S
CAS Number:
Molecular Weight:
358.54
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Product Name
Salirasib, ≥98% (HPLC)
InChI
1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+
SMILES string
O=C(O)C1=CC=CC=C1SC/C=C(C)/CC/C=C(C)/CCC=C(C)C
InChI key
WUILNKCFCLNXOK-CFBAGHHKSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
Quality Level
Related Categories
Application
Salirasib has been used as a farnesyltransferase inhibitor.
Biochem/physiol Actions
Salirasib (Farnesylthiosalicylic acid) is a RAS inhibitor that acts by dislodging the farnesylated protein from the membrane, facilitating Ras degradation. Salirasib impairs downstream signaling and suppresses growth and migration of proliferating tumor cells in in vitro and in vivo models. Salirasib (Farnesylthiosalicylic acid) has recently been shown to possess significant anti-inflammatory and anti-arthritic properties.
Salirasib (Farnesylthiosalicylic acid) is a RAS inhibitor.
Salirasib (S-trans,trans-Farnesylthiosalicylic Acid /FTS) is a synthetic small molecule that has an ability to block all forms of Ras, unlike farnesyltransferase inhibitors, which fail to inhibit K-Ras and N-Ras function due to alternative membrane-binding mechanisms. Salirasib along with gemcitabine, exhibits anti-tumor activity and biomarker modulation in preclinical models of metastatic pancreatic adenocarcinoma (PDA). It is also used as a potent therapeutic for lung cancer.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Riely G J, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 6(8), 1435-1437 (2011)
Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
Zundelevich A, et al.
Molecular Cancer Therapeutics, 6(6), 1765-1773 (2007)
Nofar Erlichman et al.
Cancers, 14(4) (2022-02-26)
Therapies targeting the PD-L1/PD-1 axis have recently been introduced to triple-negative breast cancer (TNBC) with limited efficacy, suggesting that this axis promotes tumor progression through mechanisms other than immune suppression. Here, we over-expressed WT-PD-L1 in human TNBC cells (express endogenous
Membrane localization of acetylated CNK1 mediates a positive feedback on RAF/ERK signaling.
Fischer A, et al.
Science Advances, 3(8), e1700475-e1700475 (2017)
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Haklai R, et al.
Cancer Chemotherapy and Pharmacology, 61(1), 89-96 (2008)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service